ATE282330T1 - Ernährungszusammensetzung, die einen vorläufer von anandamide enthält - Google Patents

Ernährungszusammensetzung, die einen vorläufer von anandamide enthält

Info

Publication number
ATE282330T1
ATE282330T1 AT00964172T AT00964172T ATE282330T1 AT E282330 T1 ATE282330 T1 AT E282330T1 AT 00964172 T AT00964172 T AT 00964172T AT 00964172 T AT00964172 T AT 00964172T AT E282330 T1 ATE282330 T1 AT E282330T1
Authority
AT
Austria
Prior art keywords
composition
anandamide
precursor
nutritional composition
composition containing
Prior art date
Application number
AT00964172T
Other languages
English (en)
Inventor
Alvin Berger
Gayle Crozier
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10862297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE282330(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Application granted granted Critical
Publication of ATE282330T1 publication Critical patent/ATE282330T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00964172T 1999-10-07 2000-09-14 Ernährungszusammensetzung, die einen vorläufer von anandamide enthält ATE282330T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923738.0A GB9923738D0 (en) 1999-10-07 1999-10-07 Nutritional composition
PCT/EP2000/008995 WO2001024645A1 (en) 1999-10-07 2000-09-14 Nutritional composition

Publications (1)

Publication Number Publication Date
ATE282330T1 true ATE282330T1 (de) 2004-12-15

Family

ID=10862297

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964172T ATE282330T1 (de) 1999-10-07 2000-09-14 Ernährungszusammensetzung, die einen vorläufer von anandamide enthält

Country Status (10)

Country Link
US (1) US8323680B1 (de)
EP (1) EP1221867B2 (de)
AT (1) ATE282330T1 (de)
AU (1) AU7518700A (de)
CA (1) CA2386362C (de)
DE (1) DE60016007T3 (de)
ES (1) ES2234665T5 (de)
GB (1) GB9923738D0 (de)
PT (1) PT1221867E (de)
WO (1) WO2001024645A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1523982A (zh) 2001-03-27 2004-08-25 ���������Ǵ�ѧ���»� 减少体脂和调节脂肪酸代谢的方法、化合物和组合物
WO2003007875A2 (en) * 2001-07-16 2003-01-30 Hoegestaett Edward Compounds with analgesic, antipyretic and/or anti-inflammatory activity
ATE406867T1 (de) * 2001-07-18 2008-09-15 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
WO2005018632A1 (en) 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
EP1677780A4 (de) * 2003-10-16 2007-05-02 Univ California Dietätische und andere nahrungsmittel, verbindungen und verfahren zur reduzierung des körperfetts, zur appetitzügelung und zur modulierung des fettsäurestoffwechsels
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP2098229A4 (de) 2006-12-28 2010-03-10 Suntory Holdings Ltd Nervenregenerationsmittel
WO2009124551A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
WO2009124553A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
MX2014001767A (es) * 2011-08-15 2014-05-01 Nestec Sa Metodos para reducir sintomas o condiciones causados por estres.
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
US9962355B2 (en) 2014-08-08 2018-05-08 Raffaele Migliaccio Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
ITUB20153066A1 (it) 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea
MY186286A (en) 2017-09-05 2021-07-05 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB9026648D0 (en) 1990-12-07 1991-01-23 Efamol Holdings Nutrition
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
JPH08511533A (ja) 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション 神経学的障害の治療に有用な方法および医薬用組成物
GB9510636D0 (en) 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US5688825A (en) * 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EA010267B1 (ru) * 2002-10-07 2008-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Модуляция тревоги через блокаду гидролиза анандамида

Also Published As

Publication number Publication date
PT1221867E (pt) 2005-04-29
AU7518700A (en) 2001-05-10
DE60016007T2 (de) 2006-03-02
EP1221867A1 (de) 2002-07-17
CA2386362A1 (en) 2001-04-12
WO2001024645A1 (en) 2001-04-12
ES2234665T5 (es) 2009-03-01
EP1221867B2 (de) 2008-08-20
CA2386362C (en) 2012-08-14
GB9923738D0 (en) 1999-12-08
DE60016007D1 (de) 2004-12-23
DE60016007T3 (de) 2009-07-09
EP1221867B1 (de) 2004-11-17
ES2234665T3 (es) 2005-07-01
US8323680B1 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
ATE282330T1 (de) Ernährungszusammensetzung, die einen vorläufer von anandamide enthält
DE60127457D1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
US11471432B2 (en) Supporting immunomodulatory agent
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
IL153989A (en) Nutritional composition comprising mixture of functional carbohydrates
TR200002207T1 (tr) Slekoksib bileşikleri.
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
HK1042655A1 (en) Use of erythropoietin in the production of the drugs for the treatment of cerebral ischaemia.
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
NZ507203A (en) Use of dexmedetomidine for ICU sedation
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
NO20016004D0 (no) Sammensetning som innbefatter alkalin-sfingomyelinase for anvendelse som et kostholdspreparat, n¶ringsmiddeltilskudd ellerfarmasöytisk produkt
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
ATE267162T1 (de) Therapeutisch und/oder ernährungsphysiologisch verbesserte derivate aktiver inhaltsstoffe und oral verabreichbare zusammensetzungen, die diese enthalten
EP1550443A4 (de) Zusammensetzung gegen stressbedingte erkrankungen
CA2429793A1 (en) Interferon therapeutic effect enhancer
Kiersch et al. The onset of action and the analgesic efficacy of Saridon®*(a propyphenazone/paracetamol/caffeine combination) in comparison with paracetamol, ibuprofen, aspirin and placebo (pooled statistical analysis)
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
WO2016174861A1 (ja) 口腔ケア組成物

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1221867

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1221867

Country of ref document: EP